- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06722157
Un estudio para probar si BI 771716 ayuda a las personas con una forma avanzada de degeneración macular relacionada con la edad (DMAE) llamada atrofia geográfica (VERDANT)
Estudio multicéntrico, aleatorizado, doble enmascarado, controlado activamente para evaluar la eficacia y seguridad de dos regímenes de BI intravítreo 771716 frente a pegcetacoplan en participantes con atrofia geográfica secundaria a degeneración macular relacionada con la edad Ensayo VERDANT
This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan. BI 771716 is being developed to treat people with geographic atrophy. Pegcetacoplan is a medicine already used to treat people with geographic atrophy.
In this study, participants receive either BI 771716 or pegcetacoplan as injections in the eye.
Participants are in the study for a little longer than a year and visit the study site every 4 weeks. At the visits, the study doctor checks the eyes of the participants. The results are compared between the groups of participants to see whether the treatment works. The study doctor also regularly checks participants' health and takes note of any unwanted effects.
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arizona
-
Gilbert, Arizona, Estados Unidos, 85297
- Associated Retina Consultants
-
Phoenix, Arizona, Estados Unidos, 85020
- Associated Retina Consultants, Ltd.
-
Phoenix, Arizona, Estados Unidos, 85050
- Phoenix Retina Associates
-
Scottsdale, Arizona, Estados Unidos, 85255
- Retina Macula Institute of Arizona
-
-
California
-
Glendale, California, Estados Unidos, 91204
- Global Research Management
-
Huntington Beach, California, Estados Unidos, 92647
- Retina Associates of Southern California
-
Modesto, California, Estados Unidos, 95356
- Retinal Consultants Medical Group, Inc
-
Newport Beach, California, Estados Unidos, 92663
- Eye Research Foundation
-
Poway, California, Estados Unidos, 92064
- Retina Consultants of San Diego
-
Sacramento, California, Estados Unidos, 95825
- Retinal Consultants Medical Group
-
Walnut Creek, California, Estados Unidos, 94598
- Bay Area Retina Associates - Walnut Creek
-
-
Colorado
-
Lakewood, Colorado, Estados Unidos, 80228
- Colorado Retina Associates
-
-
Connecticut
-
Danbury, Connecticut, Estados Unidos, 06810
- Connecticut Eye Consultants, PC
-
Waterford, Connecticut, Estados Unidos, 06385
- Retina Group of New England, PC
-
-
Florida
-
Deerfield Beach, Florida, Estados Unidos, 33064
- Rand Eye Institute
-
Fort Lauderdale, Florida, Estados Unidos, 33308
- Retina Group of Florida
-
Pinellas Park, Florida, Estados Unidos, 33782
- Eye Associates of Pinellas
-
St. Petersburg, Florida, Estados Unidos, 33711
- Retina Vitreous Associates of Florida
-
-
Georgia
-
Augusta, Georgia, Estados Unidos, 30909
- Southeast Retina Center, PC
-
-
Illinois
-
Lemont, Illinois, Estados Unidos, 60439
- University Retina and Macula Associates
-
Oak Park, Illinois, Estados Unidos, 60304
- Illinois Retina Associates - Oak Park
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40206
- Butchertown Clinical Trials
-
-
Maryland
-
Hagerstown, Maryland, Estados Unidos, 21740
- Mid Atlantic Retina Specialists
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Ophthalmic Consultants of Boston
-
-
Minnesota
-
Edina, Minnesota, Estados Unidos, 55435
- Retina Consultants of Minnesota
-
-
Mississippi
-
Madison, Mississippi, Estados Unidos, 39110
- Mississippi Retina Associates
-
-
Missouri
-
Columbia, Missouri, Estados Unidos, 65212
- University of Missouri Health System
-
-
New Jersey
-
Bloomfield, New Jersey, Estados Unidos, 07003
- Envision Ocular, LLC
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87109
- Eye Associates of New Mexico
-
-
New York
-
Westbury, New York, Estados Unidos, 11590
- Long Island Vitreoretinal Consultants - Westbury
-
-
Oregon
-
Eugene, Oregon, Estados Unidos, 97401
- Verum Research, LLC
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Estados Unidos, 18017
- Mid Atlantic Retina - Bethlehem
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29414
- Charleston Neuroscience Institute - Charleston
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Tennessee Retina
-
-
Texas
-
Austin, Texas, Estados Unidos, 78750
- Austin Clinical Research, LLC
-
Beaumont, Texas, Estados Unidos, 77707
- Retina Consultants of Texas - Beaumont
-
Bellaire, Texas, Estados Unidos, 77401
- Retina Consultants of Texas-Bellaire-67493
-
Dallas, Texas, Estados Unidos, 75231
- Retina Foundation of the Southwest
-
Katy, Texas, Estados Unidos, 77494
- Retina Consultants of Texas - Katy
-
Plano, Texas, Estados Unidos, 75024
- Red River Research Partners, LLC
-
San Antonio, Texas, Estados Unidos, 78240
- Retinal Consultants of San Antonio
-
Schertz, Texas, Estados Unidos, 78154
- Retina Consultants of Texas - Schertz
-
The Woodlands, Texas, Estados Unidos, 77384
- Retina Consultants of Texas-The Woodlands-67575
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84107
- Retina Associates of Utah
-
-
Virginia
-
Lynchburg, Virginia, Estados Unidos, 24502
- Piedmont Eye Center
-
-
Washington
-
Spokane, Washington, Estados Unidos, 99204
- Spokane Eye Clinic
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion criteria
-
Age at least 50 years old at the time of randomization visit
-
Signed and dated written informed consent in accordance with International Council on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
-
Male or female participants. Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of use are provided in the participant information. Male participants must be ready and able to use either a condom or abstinence as contraceptive measures
-
Diagnosis of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), where the total GA lesion area must be ≥2.5 square millimetres (mm²) and ≤17.5 mm² as measured by Fundus autofluorescence (FAF)
- If multiple lesions are present in the study eye, at least 1 lesion must have an area of ≥1.25 mm²
- Note: Fellow eye is not required to have GA
- Note: subfoveal GA lesions (defined as GA lesions within 1 micron of the foveal center point) will be allowed to be enrolled until a maximum of approximately 60% of participants with subfoveal GA lesions are enrolled. Participants with subfoveal GA lesions already in screening at the time the cap has been reached may be considered for randomization.
-
Fellow eye must have sufficient visual function compared to the study eye, per the investigator's medical judgment in consultation with the patient, to support the patient's daily functioning
-
BCVA letter score of ≥24 letters, using the ETDRS chart in the study eye (equivalent to ≥20/320 on the Snellen chart). Note: If both eyes meet eligibility criteria, the eye with the worse visual function per the investigator's medical judgment in consultation with the patient, will be selected as the study eye. If both eyes have similar visual function, the study eye will be selected per the investigator's medical judgment in consultation with the patient
-
further inclusion criteria apply
Exclusion criteria
-
GA lesions whose area cannot be accurately defined in the study eye
-
Exudative neovascular AMD (eAMD) in the study eye
-- Note: eAMD in the fellow eye is allowed. However, if the fellow eye is to be considered for microperimetry and other analyses (as defined in the trial statistical analysis plan), then eAMD is not allowed in either eye.
-
Previously received treatment in the study eye for GA secondary to AMD within 4 months or 5 half-lives prior to baseline, whichever is longer
-
Previously received an investigational medication (oral or intravitreal) for GA secondary to AMD within 4 months or 5 half-lives prior to baseline, whichever is longer
-
Currently enrolled in another investigational device or drug trial, or 30 days or 5 half-lives, whichever is longer since ending another investigational device or drug trial(s) or receiving other investigational treatment(s). Any previous use of gene therapy or cell therapy is not permitted
-
Additional eye disease as follows:
- Any eye disease in the study eye that could compromise BCVA
- Uncontrolled glaucoma or ocular hypertension with intraocular pressure >24 millimetre of mercury (mmHg) in study eye
- History of high myopia >8 diopters in the study eye
- Anterior segment and vitreous abnormalities that would preclude adequate observation with spectral domain optical coherence tomography in the study eye
- Ocular conditions at the discretion of the investigator that might interfere with outcome of the trial in the study eye
- Active intraocular inflammation in the study eye
- Active infectious conjunctivitis in either eye
-
Prior vitrectomy surgery in the study eye
-
History of major intraocular surgeries including major corneal surgery. Uneventful cataract surgery, refractive surgery, oculoplastic surgery, strabismus surgery, and other extraocular surgery may be permitted if they have occurred more than 3 months prior to baseline in the study eye
-
further exclusion criteria apply
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Brazo A: BI 771716
|
BI 771716 |
|
Experimental: Brazo B: BI 771716 y comparador Sham
|
BI 771716 Sham comparator to BI 771716 |
|
Comparador activo: Grupo C: Pegcetacoplan
|
Pegcetacoplan
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Pendiente de cambio desde el valor inicial en el área de atrofia geográfica (GA) transformada con raíz cuadrada medida por autofluorescencia del fondo de ojo (FAF) en el ojo del estudio expresada en milímetros (mm)/año
Periodo de tiempo: Al inicio, en la semana 56
|
Al inicio, en la semana 56
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Cambio desde el valor inicial en el área GA transformada con raíz cuadrada medida por FAF en el ojo del estudio expresado en mm
Periodo de tiempo: Al inicio, en la semana 56
|
Al inicio, en la semana 56
|
|
Cambio desde el valor inicial en la agudeza visual mejor corregida (MAVC) medida por el cuadro estandarizado del estudio de retinopatía diabética de prueba temprana (ETDRS) en el ojo del estudio
Periodo de tiempo: Al inicio, en la semana 56
|
Al inicio, en la semana 56
|
|
Aparición de pérdida de letras BCVA de ≥15 letras según lo medido por el gráfico ETDRS estandarizado en el ojo del estudio durante al menos 2 visitas consecutivas
Periodo de tiempo: Hasta la semana 56
|
Hasta la semana 56
|
|
Aparición de degeneración macular relacionada con la edad (DMAE) neovascular exudativa en el ojo del estudio desde la primera administración del fármaco hasta la semana 56
Periodo de tiempo: Hasta la semana 56
|
Hasta la semana 56
|
|
Aparición de eventos adversos (EA) relacionados con el fármaco desde la primera administración del fármaco hasta la semana 56
Periodo de tiempo: Hasta la semana 56
|
Hasta la semana 56
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 1497-0002
- U1111-1308-7923 (Identificador de registro: WHO International Clinical Trials Registry Platform (ICTRP))
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Once the criteria in section 'time frame' are fulfilled, researchers can use the following link https:// www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
Marco de tiempo para compartir IPD
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
Criterios de acceso compartido de IPD
For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .